Is Asiminib a targeted drug or a chemotherapy drug?

Asciminib (Asciminib) is a targeted drug, not a chemotherapy drug. It is a kinase inhibitor targeting the BCR-ABL fusion gene. By inhibiting BCR-ABL kinase activity, it prevents tumor cell proliferation, thereby achieving the effect of treating chronic myelogenous leukemia (CML). Unlike traditional chemotherapy drugs, targeted drugs act specifically on specific targets of tumor cells and have relatively little toxic side effects on normal cells.

These latest results from ASCEMBL confirm the durable clinical benefit of acesiminib after long-term exposure and continue to illustrate that acesiminib has transformed CML treatment into a new standard of care for patients with CML-CP who have received ≥2 prior TKIs, and supports its continued development in early-stage treatment. In clinical studies of aceminib in previously treated patients with Ph+CML-CP, the most common (≥20%) adverse reactions were upper respiratory tract infection, musculoskeletal pain, headache, and fatigue.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in the medical insurance. The original drug of Asiminib sold overseas is very expensive. The price of 20mg*60 oral tablets is about more than 20,000 US dollars, which is about 150,000 yuan in RMB. There are also Assimini generic drugs produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rates). The price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.